http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2472792-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf4c4bead673d9c69f22862f2f6cd4ea http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a4fb1d9a2c1177911aa4c047bdfd450d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 |
| filingDate | 2008-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3bf53980264e3bd5a16831540d00356 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3c7c35dc2dba2afc218f27cde562bce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8019b2832a7e470f5ae4ec1b16ed13f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c97554748418ff40c02e68d00951c9d |
| publicationDate | 2013-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2472792-C2 |
| titleOfInvention | 2-(2-oxoindolin-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-ylpropyl)-6,7-dihydro-1-h-pyrrole[3,2-c]pyridin-4(5h)-one compounds and use thereof as protein kinase inhibitors |
| abstract | FIELD: chemistry. n SUBSTANCE: invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof: where: each of R 1 , R 2 , R 3 , R 4 is independently selected from a group consisting of a hydrogen atom, a halogen atom, an aryl, a C 5-6 heteroaryl having 1-3 heteroatoms in the ring which are selected from O, S and N, -OR 5 , -NR 5 R 6 , and -NR 5 COR 6 , where said aryl or C 5-6 heteroaryl, having 1-3 heteroatoms in the ring selected from O, S and N, is unsubstituted or additionally substituted with one or more groups selected from a group consisting of alkyl, alkoxyl and halogen, each of R 5 and R 6 is independently selected from a group consisting of a hydrogen atom or an alkyl, where said alkyl is unsubstituted or additionally substituted with one or more groups selected from a group consisting of an aryl, haloaryl, hydroxyl and alkoxyl. The invention also relates to a pharmaceutical composition which inhibits protein kinase and contains a compound of formula I, a method of producing the compound of formula I, use of said compounds to produce a medicinal agent for treating disorders associated with protein kinase, and a method of modulating catalytic activity of protein kinase. n EFFECT: improved method. n 10 cl, 24 ex |
| priorityDate | 2007-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 319.